看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。% J) q2 K$ q" _
6 { w1 W# `, g+ `, \. M' t
p3 X, I# h; w( |Currently available feasibility data for possible combination strategies.
( C. E/ u& S/ M————————————————————————————————
" @) |6 k9 z/ ~; v8 Q3 W) lCombination Feasibility according to preliminary data 4 e% l \5 K7 `- M$ L: n1 x( q" R7 q
——————————————————————————————————# Q2 s3 t% ~% M! s
Bevacizumab + sorafenib Yes, reduced dose 9 |% M8 J" l( V9 D& ?4 A
Bevacizumab + sunitinib† No " S" U. d7 i* i/ K1 a
Bevacizumab + temsirolimus Yes 4 }: `- D$ M* j5 k# M2 I( y5 h( F! T
Bevacizumab + everolimus Yes " R& P F q b u/ W
Sorafenib + sunitinib ? ( E( v k& ^0 [+ a
Sorafenib + temsirolimus Yes, reduced dose - e, X- k8 x' y' P, d4 @
Sorafenib + everolimus Yes, reduced dose
. i; o! o; a0 S" LSunitinib + temsirolimus† No
7 F. O. k6 \0 ?+ w9 s H% uSunitinib + everolimus ?
8 _3 @3 P2 k( T8 U3 iTemsirolimus + everolimus ?
+ D: G. U! W5 Y3 U& n5 L" q————————————————————
: D: T+ V9 M) Q- y†Led to US FDA warning.
# [3 L7 n1 ^) h( m2 M?: As yet unattempted combination.! Y' a, W4 Z$ N! T0 I
|